Opening an infusion center requires navigating a layered process of state licensing, facility design, federal compliance, and payer contracting, often with a total startup investment in the range of $500,000 or more before you see your first patient. The timeline from initial planning to opening day typically runs 12 to 18 months, depending on your state’s regulatory requirements and whether you need construction or renovation. Here’s what each stage involves.
Licensing and Certificate of Need
Every state regulates outpatient healthcare facilities, but the specific license you need varies. Some states classify freestanding infusion centers under an outpatient diagnostic and treatment center license, while others may require an ambulatory surgical treatment center license even if you’re not performing surgery. Contact your state’s health facilities commission or department of health early, because the application process alone can take several months.
Beyond the basic facility license, some states require a Certificate of Need (CON) before you can open. A CON process asks you to demonstrate that your community actually needs the services you plan to offer, and the review involves public comment periods, financial projections, and sometimes hearings. Not every state has CON requirements, but those that do can add six months or more to your timeline. Checking this first prevents you from signing a lease on a space you can’t legally operate in.
If your center will compound sterile medications on-site (mixing IV bags, for example), you’ll also need a pharmacy license for that space and a pharmacist-in-charge. Some operators avoid this by outsourcing compounding to a specialty pharmacy, but that choice shapes your entire business model.
Federal Compliance: Stark Law and Anti-Kickback
Two federal statutes heavily influence how an infusion center can be structured, especially when physicians have ownership stakes or referral relationships. Getting these wrong carries criminal penalties and exclusion from Medicare and Medicaid.
The Anti-Kickback Statute makes it illegal to offer or receive anything of value in exchange for patient referrals to services covered by federal health programs. An arrangement where a physician receives compensation tied to how many patients they send to your infusion center would be a clear violation. The Stark Law takes a slightly different angle: if a physician (or their immediate family member) has a financial relationship with an entity, that physician cannot refer Medicare or Medicaid patients to that entity for designated health services, and the entity cannot bill for those services. Infusion therapy falls under this umbrella.
Both laws have safe harbors and exceptions that allow legitimate business arrangements, but the structures must be carefully designed. Physician ownership models, medical director compensation, and space-sharing agreements all need review by a healthcare attorney experienced in these statutes before you finalize your business entity.
Choosing a Drug Procurement Model
How you acquire and get paid for the medications you administer is one of the most consequential financial decisions you’ll make. The two primary models are buy-and-bill and white bagging.
In a buy-and-bill model, your center purchases drugs directly from a manufacturer or wholesaler, stores them, prepares them, and administers them. You then bill the patient’s medical insurance for both the drug and the administration. The margin between your purchase price and the payer’s reimbursement rate is a significant part of your revenue. For many infusion practices, drug markups help cover the real costs of shipping, storage, mixing, and inventory tracking. However, you’re also carrying inventory risk: if a patient cancels or a drug expires, you absorb that cost.
White bagging is a newer model driven by insurance companies. Here, the payer directs a specialty pharmacy to purchase the drug and ship it to your center already assigned to a specific patient. Your center can only bill for the administration, not the drug itself, because the medication runs through the patient’s pharmacy benefit instead of their medical benefit. This lowers costs for insurers, but research has shown it can increase out-of-pocket costs for patients. It also reduces your revenue per infusion and creates logistical complications: you’re responsible for verifying and administering a drug you didn’t purchase or compound, and if the patient no-shows, the drug may go to waste.
Most centers use a mix of both models depending on payer contracts. Understanding how each major insurer in your market handles specialty drug procurement will shape your financial projections.
Facility Design and Sterile Compounding Standards
An infusion center’s physical space needs to accommodate patient treatment areas, a nursing station with clear sightlines, secure drug storage, and potentially a sterile compounding room. If you plan to mix IV medications on-site, your facility must meet the standards set by USP 797 (sterile compounding) and USP 800 (hazardous drug handling).
The 2023 update to USP 797 tightened requirements considerably. A cleanroom suite needs an ISO Class 7 buffer room within a controlled environment, hands-free access doors, air exchange rates of at least 20 changes per hour in ISO Class 8 rooms, humidity maintained at 60% or below, and tightly controlled pressure differentials. If you’re handling hazardous drugs like certain chemotherapy agents, USP 800 requires a separate negative-pressure space. You can no longer prepare even low volumes of hazardous drugs outside of one.
Building a compliant cleanroom adds significant cost to your buildout. Some centers choose to avoid on-site compounding entirely by using an outside pharmacy, which eliminates the cleanroom requirement but introduces dependency on a third-party supplier and limits your scheduling flexibility.
Startup Costs
The two largest upfront expenses are clinic buildout and medical equipment. A typical clinic fit-out, covering construction, plumbing for infusion stations, cleanroom construction if applicable, and general interior work, runs around $350,000. Medical equipment, including infusion pumps, infusion chairs, monitoring devices, and clinical disposables, adds roughly $180,000. On top of that, you’ll have costs for furniture, IT systems, electronic health records, initial licensing fees, legal and consulting fees, and working capital to cover payroll and drug inventory before reimbursements start flowing.
Drug inventory is a variable cost that depends on your service mix. A center focused on immunoglobulin infusions or biologics for autoimmune conditions will need a much larger initial drug investment than one focused on iron infusions or hydration therapy. Sterile compounding supplies represent an ongoing cost of goods rather than a fixed startup expense, but you’ll need initial stock on hand before opening.
All told, plan for a minimum of $500,000 to $750,000 to get through the door, with the higher end applying to centers that include on-site compounding or serve oncology patients.
Staffing and Medical Direction
You’ll need a medical director, which is typically a physician who oversees clinical protocols, standing orders, and quality assurance. The medical director doesn’t need to be on-site for every infusion, but they must be available and engaged in policy development. Their compensation structure needs to comply with fair market value requirements under Stark and Anti-Kickback rules.
For nursing, a staffing ratio of roughly one registered nurse to six patients is a common target for outpatient chemotherapy and infusion centers. Research from a major cancer center staffing model found that this 1:6 ratio balanced quality care with operational efficiency after clearly defining the infusion nurse’s role and eliminating tasks that could be delegated to other staff. Your actual ratio will depend on the acuity of your patient population. Complex oncology infusions with high reaction risk need closer monitoring than routine iron or antibiotic infusions.
Beyond RNs, you’ll likely need a scheduler or patient coordinator, a billing specialist familiar with specialty drug reimbursement, and either a pharmacist or a relationship with an external pharmacy. Many centers start lean and add staff as volume grows.
Accreditation
Accreditation isn’t legally required in most states, but many payers won’t contract with an unaccredited infusion center. The three nationally recognized accreditation organizations are the Accreditation Commission for Health Care (ACHC), the Community Health Accreditation Partner (CHAP), and The Joint Commission. Each sets standards covering patient safety, infection control, medication management, and operational policies, though their survey processes and costs differ.
ACHC is popular among smaller, independent infusion centers because its process tends to be more consultative and less expensive than The Joint Commission. The Joint Commission carries strong brand recognition and may be preferred by larger payer networks. Whichever you choose, plan for the accreditation survey to happen after you’ve been operational long enough to demonstrate your policies in action, typically three to six months after opening.
Insurance Contracting and Prior Authorization
Payer contracting is where many new infusion centers hit unexpected delays. You need to be credentialed with commercial insurers, Medicare, and Medicaid before you can bill for services, and the credentialing process for a new facility can take 90 to 120 days per payer. Start applications as early as your state license allows.
Once operational, prior authorization becomes a daily workflow. Most specialty infusion drugs require the insurer’s approval before administration. Your staff will verify insurance coverage, submit prior authorization requests, and manage denials. A study of infusible medications for rheumatic diseases found that when prior authorizations were denied, about 79% were overturned through a peer-to-peer discussion between the prescribing physician and the insurer’s medical reviewer. Building a systematic process for tracking authorization status, following up on pending requests, and escalating denials quickly is essential. Treatment delays from slow prior authorization are one of the biggest sources of patient dissatisfaction and scheduling disruption.
Billing and Reimbursement Basics
Infusion billing uses two layers of codes. Administration codes (CPT codes) cover the act of setting up an IV, monitoring the patient, and managing the infusion. Drug codes (HCPCS J-codes) identify the specific medication administered and its dosage. You bill both for each visit under buy-and-bill arrangements, and only the administration codes under white bagging.
CMS groups home infusion drugs into three payment categories based on their J-code: category 1 covers drugs like long-term IV antibiotics, antifungals, pain management, and chelation therapy; category 2 covers subcutaneous immunotherapy; and category 3 covers certain chemotherapy drugs. Each category has corresponding service codes that determine the professional services reimbursement rate. Accurate coding matters enormously. Undercoding leaves money on the table, while upcoding triggers audits and potential fraud liability. Investing in a coder or billing service with infusion-specific experience pays for itself quickly.